TRIM24/BRPF1-IN-2

CAS No. 3033288-68-2

TRIM24/BRPF1-IN-2( —— )

Catalog No. M36595 CAS No. 3033288-68-2

TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 922 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TRIM24/BRPF1-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.
  • Description
    TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3033288-68-2
  • Formula Weight
    386.47
  • Molecular Formula
    C20H22N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(N1C2=CC=C(C=C2CC1)NS(=O)(=O)C3=CC(=CC=C3OC)C4CC4)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • GSK620

    GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.

  • Alobresib

    Alobresib is an inhibitor of BET bromodomain,is an antineoplastic drug candidate.

  • SR-0813

    SR-0813 is a potent and selective inhibitor of the YEATS domain in ENL/AF9, with an IC50 of 25 nM and EC50 of 205 nM for the ENL YEATS domain, and an IC50 of 311 nM and EC50 of 76 nM (CETSA) for the AF9 YEATS domain.